HOME >> MEDICINE >> NEWS
Derivatives of cannabis for anti-cancer treatment win Kaye Award for Hebrew University student

Derivatives of the cannabis plant (hashish) have been shown by a Hebrew University of Jerusalem Ph.D. student to be effective in arresting cancerous growths in laboratory and animal tests.

For her work, Natalya Kogan was one of the winners of a Kaye Innovation Award, presented today during the 68th meeting of the Hebrew University Board of governors.

Working under the supervision of Prof. Raphael Mechoulam at the Hebrew University School of Pharmacy (in collaboration with Prof. Michael Schlesinger at the Hebrew University-Hadassah Medical School and Prof. Ester Priel at Ben-Gurion University of the Negev), Kogan has developed new compounds known as quinonoid cannabinoids that parallel in their activity a group of anti-cancer drugs, the best known of which is daunomycin.

However, while daunomycin is toxic to the heart, Kogan, with Dr. Ronen Beeri and Dr. Gergana Marincheva of Hadassah University Hospital, Ein Kerem, found that the quinonoid cannabinoids are much less cardiotoxic. The development of quinonoid compounds that display anticancer activity, but are less toxic, is a major therapeutic goal. At present, Kogan is continuing to investigate the mechanism of action of these promising compounds.

All of the compounds synthesized by Kogan inhibited cancer cell growth in cell culture, and one of them was found to markedly reduce the volume of tumors in animal studies The cannabinoid quinones were found to act through a rather unique pathway of cancer cell destruction -- by specific inhibition of topoisomerase II, an enzyme that participates in cell replication. Most of the known anti-cancer drugs are less selective, acting by numerous mechanisms.

Additionally, the most active compound in the series developed by Kogan, as well as some other cannabinoids, were found by Kogan and Prof. Ruth Galilli of the Hebrew University to have anti-angiogenic properties. Angiogenesis, the process of new blood vessel formation, is cr
'"/>

Contact: Jerry Barach
972-2-588-2904
The Hebrew University of Jerusalem
6-Jun-2005


Page: 1 2

Related medicine news :

1. Smokeless cannabis delivery device efficient and less toxic
2. Imaging technique sheds new light on the composition of the brain of moderate cannabis users
3. New antidepressant drug increases brains own cannabis
4. New algorithm matches any tumor cells to best possible anti-cancer treatments
5. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
6. Vorinostat shows anti-cancer activity in recurrent gliomas
7. Research says boiling broccoli ruins its anti-cancer properties
8. Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
9. Mistletoe is not an anti-cancer drug, say doctors
10. Erectile dysfunction drugs heighten natural anti-cancer activity
11. New litmus test could aid discovery of anti-cancer drugs

Post Your Comments:
(Date:4/27/2015)... Launched by a group of ... consumers a way to connect to top local ... a patent-pending Pick Your Price matching algorithm, clients ... laser hair removal and dermal fillers on days ... in their schedules. This allows clients to take ...
(Date:4/26/2015)... has released a new blog post explaining how to find ... to find low cost auto insurance is by comparing quotes. ... in a simple and convenient way. It is no longer ... prices. All the details are now freely available to anyone ... possible to compare online car insurance quotes on a single ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in the ... the Asian Indian community in the United States and ... two decades. The India News Network Digest of 1990s ... world with the latest news items from India, the ... Forum Digest, edited and contributed by Sheela Murthy, helped ...
(Date:4/26/2015)... 2015 MidSouth Pain Treatment Center ... Southeast. MidSouth Pain Treatment Center is a comprehensive pain ... Oxford and Jackson, two ambulatory surgery centers in Germantown ... and Cordova locations. , Dr. Michael Steuer , ... medicine to help people, and when I discovered that ...
(Date:4/25/2015)... Washington, D.C. (PRWEB) April 25, 2015 ... for Bangladesh Worker Safety issues the following statement following ... 7.8 earthquake hit Kathmandu, Nepal, resulting in the deaths ... this massive earthquake were felt across Nepal, Bangladesh, India ... to offer my heartfelt condolences to the people of ...
Breaking Medicine News(10 mins):Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:Growing Pains for MidSouth Pain Treatment Center 2
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... , April 23, 2015 Once again, BeaconMedaes ... our commitment to patient safety. BeaconMedaes, priority ... against infectious disease. The next generation Zone ... gas sensors are now mounted in the assembly, allowing ... to open ceiling tiles potentially releasing dust spores and ...
(Date:4/23/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its ... on Thursday, April 30, 2015, after the close of U.S.-based ... officer, will host a conference call to review the results ... (PT). The press release and a live ... a link that is posted on the home page and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
Cached News: